Skip to main content

Table 5 Cox regression analyses of progression-free survival in cervical squamous cell carcinoma patients

From: Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma

Factor PFS OS
HR
(95%CI)
P-value HR
(95%CI)
P-value
Age 5.423
(1.113–26.419)
0.036 4.265
(0.901–20.194)
0.067
Family history of cancer
History of miscarriage 0.521
(0.150–1.809)
0.304 0.735
(0.208–2.600)
0.634
Tumor size 1.629
(0.443–5.598)
0.463 2.310
(0.571–9.345)
0.240
Tumor type 0.947
(0.400–2.239)
0.901 0.594
(0.194–1.820)
0.362
Histologic grade 0.922
(0.374–2.271)
0.860 0.772
(0.291–2.045)
0.602
FIGO stage 1.031
(0.221–4.804)
0.969 0.934
(0.196–4.450)
0.931
SCC-Ag 0.720
(0.067–7.774)
0.787 0.931
(0.086–10.035)
0.953
CEA 0.766
(0.194–3.015)
0.702 1.902
(0.342–10.581)
0.463
TSGF 0.381
(0.096–1.515)
0.171 0.657
(0.154–2.808)
0.571
Pelvic lymph nodes 5.035
(1.140–22.231)
0.033 2.844
(0.571–14.166)
0.202
HPV E1-specific T cell response 7.252
(1.690–31.126)
0.008 7.499
(1.661–33.856)
0.009
Treatment 1.595
(0.532–4.784)
0.405 0.118
(0.347–3.603)
0.851
  1. FIGO International Federation of Gynecology and Obstetrics, SCC-Ag Squamous cell carcinoma antigen, CEA carcinoembryonic antigen, TSGF Tumor specific growth factor, HPV Human papillomavirus